Table 1.
Published clinical trials in solid tumors
| Trial number | Cancer entity | Published | CAR Target molecule |
Trial Phase |
Patients N |
Outcome | Reference |
|---|---|---|---|---|---|---|---|
| NCT01869166 | Biliary tract cancer | 2018 | EGFR | I | 19 |
1/17 complete remission 10/17 stable disease |
[36] |
| NCT02349724 | CRC | 2017 | CEA | I | 10 | 7/10 stable disease | [15] |
| NCT01212887 | GI tumors | 2017 | CEACAM5 | I | 14 |
No objective clinical response Terminated due to safety concerns |
[37] |
| NCT02541370 | GI tumors | 2018 | CD133 | I | 23 |
3/23 partial response 14/23 stable disease |
[38] |
| NCT00730613 | Glioblastoma | 2015 | IL13Rα2 | I | 3 | No objective clinical response | [16] |
| NCT02209376 | Glioblastoma | 2017 | EGFRvIII | I | 10 | Not available due to surgical intervention | [17] |
| NCT01109095 | Glioblastoma | 2017 | HER-2/neu | I | 17 |
1/17 partial response 7/17 stable disease |
[39] |
| NCT01454596 | Glioblastoma | 2019 | EGFRvIII | I | 18 | No objective clinical response | [21] |
| NCT02395250, NCT03146234 | HCC | 2020 | GPC3 | I | 13 |
2/13 partial response, 1/13 stable disease |
[40] |
| Park et al. | Neuroblastoma | 2007 | L1-CAM | I | 6 | 1/6 stable disease then partial response | [41] |
| Pule et al. | Neuroblastoma | 2008 | GD2 | I | 11 | 4/8 evidence of regression | [42] |
| NCT00085930 | Neuroblastoma | 2011 | GD2 | I | 19 | 3/19 complete remission | [43] |
| NCT01822652 | Neuroblastoma | 2017 | GD2 | I | 11 | 5/11 stable disease | [44] |
| NCT01869166 | NSCLC | 2016 | EGFR | I | 11 |
2/11 partial response 5/11 stable disease |
[18] |
| Kershaw et al. | Ovarian Carcinoma | 2006 | FRα | I | 14 | No objective clinical response | [45] |
| NCT01897415 | PDAC | 2018 | MSLN | I | 6 | 2/6 stable disease | [46] |
| NCT01869166 | PDAC | 2020 | EGFR | I | 14 |
4/14 partial response 8/14 stable disease |
[14] |
| Junghans et al. | Prostate cancer | 2016 | PSMA | I | 5 (6) | 2/5 partial response | [47] |
| Lamers et al. | RCC | 2016 | CAIX | I | 12 | No objective clinical response | [48] |
| NCT00902044 | Sarcomas | 2015 | HER-2/neu | I | 17 (19) | 4/17 stable disease | [49] |
| NCT02159716 | Solid tumors | 2019 | MSLN | I | 15 | 11/15 stable disease | [50] |
CRC Colorectal Carcinoma, GI tumor, Gastrointestinal Tumor, HCC Hepatocellular Carcinoma, NSCLC Non-Small Cell Lung Cancer, PDAC Pancreatic Ductal Adenocarcinoma, RCC Renal Cell Carcinoma, IL13Ra2 Interleukin-13 receptor subunit alpha 2, L1-CAM L1 Cell Adhesion Molecule, HER2/neu Human epidermal growth factor receptor 2, EGFR(vIII) Epidermal Growth Factor Receptor (variant III), CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5, MSLN Mesothelin, CEA Carcino-Embryonic Antigen, GPC3 Glypican‑3, CAIX Carboxyanhydrase-IX, FRα α-folate Receptor, PSMA Prostate-specific membrane antigen